A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Farletuzumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Morphotek
- 31 Mar 2014 Status changed to completed as reported by ClinicalTrials.gov.
- 28 Jan 2014 Status changed from active, no longer recruiting to discontinued as reported by the European Clinical Trials Database record.
- 01 Nov 2013 Planned end date changed from 1 Jan 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History